European Urology Oncology

@EurUrolOncol

Sister journal to • EiC Prof. Alberto Briganti • Official journal of ESOU •

europeanurology.com/euoncology
Vrijeme pridruživanja: travanj 2015.
329 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @EurUrolOncol

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EurUrolOncol

  1. Prikvačeni tweet
    26. stu 2019.

    The latest issue of is now available for download! Featuring: : RCTs of -targeted vs systematic biopsy : role of variant histology in MIBC : 1st line treatment of mRCC Happy reading!

    , , i još njih 2
    20 proslijeđenih tweetova 29 korisnika označava da im se sviđa
    Poništi
  2. proslijedio/la je Tweet
    prije 2 sata

    Today, on , I will be participating in the discussion on the . Early detection has to be included in 's Beating Cancer Plan.

    Korisnici , , i
    5 proslijeđenih tweetova 8 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    prije 4 sata

    Interesting infographic. Shows the burden urologists have with 3 of the top 8 cancers being urological.

    3 urological cancers are among the top 10 most common cancers in Europe: Prostate, Bladder and Kidney. Every person matters. Every action counts. That is why we constantly update the EAUguidelines. ▶️
    8 proslijeđenih tweetova 13 korisnika označava da im se sviđa
    Poništi
  4. proslijedio/la je Tweet
    prije 3 sata

    4 February 2020: World Cancer Day It is the 20th anniversary of . This special day highlights the "need for access to quality care, funding for cancer research and greater understanding." 🤜

    4 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  5. proslijedio/la je Tweet
    prije 7 sati

    Today is World Cancer Day. Share your reasons for specializing in treating genitourinary cancers by leaving a comment below.

    1 reply 5 proslijeđenih tweetova 5 korisnika označava da im se sviđa
    Poništi
  6. proslijedio/la je Tweet
    prije 7 sati

    3 urological cancers are among the top 10 most common cancers in Europe: Prostate, Bladder and Kidney. Every person matters. Every action counts. That is why we constantly update the EAUguidelines. ▶️

    88 proslijeđenih tweetova 90 korisnika označava da im se sviđa
    Poništi
  7. proslijedio/la je Tweet
    prije 17 sati

    Most angiomyolipoma can be monitored without any active treatment. The 4cm cutoff for intervention is not valid. Bleeding risk is only 2%. Nephron-sparing surgery or embolization are the preferred treatment options ⁦⁩ ⁦⁦⁩

    1 reply 17 proslijeđenih tweetova 38 korisnika označava da im se sviđa
    Poništi
  8. proslijedio/la je Tweet
    prije 10 sati

    Excellent review in the treatment of angiomyolipomas, these data point to overtreatment

    3 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  9. proslijedio/la je Tweet
    prije 18 sati

    HIFU treatment for in English cohort study (N=1990): stricture in 10.3%, urinary fistula in 1.3%, deferred surgery or radiation in 17.8%. Read more 👇

    8 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  10. proslijedio/la je Tweet
    31. sij

    I am a supporter and I will take action to raise awareness about bladder cancer!

    9 proslijeđenih tweetova 26 korisnika označava da im se sviđa
    Poništi
  11. proslijedio/la je Tweet
    1. velj

    BLADDER ART (NCT03333356) phase II trial in the treatment of MIBC patients with adjuvant radiotherapy is enrolling. To learn more, visit the protocol at clinical trial website.

    1 reply 13 proslijeđenih tweetova 23 korisnika označavaju da im se sviđa
    Poništi
  12. proslijedio/la je Tweet
    2. velj

    Patients w/ cT3 and/or pT3N0M0 harbor worse 3-5yr CSS & Bladder Rec Free Survival when RNU is performed laparoscopically compared to Open Read more 👇

    13 proslijeđenih tweetova 25 korisnika označava da im se sviđa
    Poništi
  13. 1. velj

    . Defining the Most Informative Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After RP @

    9 proslijeđenih tweetova 11 korisnika označava da im se sviđa
    Poništi
  14. proslijedio/la je Tweet
    31. sij

    Proposed surveillance schedule following treatment for RCC, taking into account patient risk profile and treatment efficacy.

    1 reply 40 proslijeđenih tweetova 60 korisnika označava da im se sviđa
    Poništi
  15. proslijedio/la je Tweet
    30. sij

    Are Molecular Markers for Ready for Prime Time? Nathan Brooks

    17 proslijeđenih tweetova 31 korisnik označava da mu se sviđa
    Poništi
  16. proslijedio/la je Tweet
    30. sij

    In this webcast, 3 real-life clinical cases were discussed on the contemporary key topics in (PN) from a surgical point of view. 👇

    5 proslijeđenih tweetova 11 korisnika označava da im se sviđa
    Poništi
  17. proslijedio/la je Tweet
    29. sij

    Gender disparities in clinical outcomes after cystectomy. by of Bukavina et. al. article in . on UroToday >

    4 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  18. proslijedio/la je Tweet
    29. sij

    Great News: Janssen Announces EMA Approval for Expanded Use of Erleada® (apalutamide) for treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

    28 proslijeđenih tweetova 77 korisnika označava da im se sviđa
    Poništi
  19. 28. sij

    most cited articles: Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes.

    5 proslijeđenih tweetova 8 korisnika označava da im se sviđa
    Poništi
  20. proslijedio/la je Tweet
    28. sij

    Increase vegetable consumption and risk of progression of early stage . Results from the MEAL randomized trial. Read more 👇

    4 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  21. proslijedio/la je Tweet
    28. sij

    . published first on in 2000 covering both and . Since these conditions require different treatment strategies, the first was produced in 2004 and now updated every year based on and

    15 proslijeđenih tweetova 36 korisnika označava da im se sviđa
    Poništi

@EurUrolOncol još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·